openPR Logo
Press release

Primary Biliary Cholangitis (PBC) Treatment Market to Witness Steady Growth through 2027

12-21-2017 07:36 AM CET | Health & Medicine

Press release from: Future Market Insights

/ PR Agency: Future Market Insights
Primary Biliary Cholangitis (PBC) Treatment Market to Witness

Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally diagnosed during routine blood examination which presents symptoms like fatigue, pertussis, and right upper quadrant discomfort. In initial examination finding the disease is normal, as the disease advances present symptoms of liver cirrhosis. The hallmark of primary biliary cirrhosis is the presence of antimitochondrial antibodies (AMAs) in the blood. Medical management of primary biliary cirrhosis mainly done to slow the symptom progression and to alleviate the symptoms.

Primary Biliary Cholangitis Treatment Market: Drivers and Restraints

Global primary biliary cholangitis treatment market is expected to drive by highly unmet medical need owing lack of definitive treatment, advanced diagnostic process coupled rising awareness among healthcare professionals and patients alike across the globe. The Incidence and prevalence of primary biliary cholangitis vary geographically, ranging from 0.7 to 49 and 6.7 to 402 per million, respectively. The factors currently contributing to the revenue growth of the primary biliary cholangitis treatment market is increasing incidence and prevalence of the disease, increased exposure to environmental triggers to immune system such as pesticides. Furthermore, lifestyle changes like smoking, alcoholism, and obesity are expected to drive the market for primary biliary cholangitis treatment over the forecast period.

Request Report TOC @ https://www.futuremarketinsights.com/toc/rep-gb-3773

Global primary biliary cholangitis treatment market hindered by the lack of definitive treatment for the disease and late diagnosis of the disease led to treatment deprivation to the patient. The market restrained by dearth of epidemiology data which helps to assess the product access and availability in various geographies which are expected to hinder market revenue growth of primary biliary cholangitis treatment over the forecast period

Primary Biliary Cholangitis Treatment Market: Overview

Global primary biliary cholangitis treatment market is witnessing significant changes due to recent approval of UDCA by several regulatory authorities across the globe. In May 2016, the FDA approved obeticholic acid in combination with UDCA for primary biliary cholangitis (PBC) in adult patients with an inadequate response to UDCA. U.K’s NICE (National Institute for Health and Care Excellence) and European Commission granted the market authorization for Ocaliva (obeticholic acid) form Intercept Pharmaceuticals, Inc. in the year 2017 and 2016 respectively.

Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-3773

Primary Biliary Cholangitis Treatment Market: Region-wise Outlook

Geographically, Primary biliary cholangitis treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Western Europe will remain key markets for primary biliary cholangitis treatment products due to increased regulatory approvals for treatment options, increasing awareness among patient advocacy groups regarding primary biliary cholangitis helps to maintain larger market share in the globalprimary biliary cholangitis treatment market by the regions. Asia Pacific is anticipated to present better growth opportunity owing to large untapped market, increasing out of pocket expenditure, and growing government’s interventions for improving healthcare infrastructure in the region.

Primary Biliary Cholangitis Treatment Market: Key Players

Some of the players in the global primary biliary cholangitis treatment market are Intercept Pharmaceuticals, Inc., Actavis, Inc., Teva Pharmaceuticals Inc., Epic Pharma, LLC, Mylan Pharmaceuticals Inc., and Axcan Scandipharm Inc. to name a few.

Pre Book Full Report – https://www.futuremarketinsights.com/checkout/3773

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website :www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis (PBC) Treatment Market to Witness Steady Growth through 2027 here

News-ID: 870749 • Views:

More Releases from Future Market Insights

Extruded Snacks Market to Reach USD 170.3 Billion by 2035 Amid Health and Convenience Revolution
Extruded Snacks Market to Reach USD 170.3 Billion by 2035 Amid Health and Conven …
A new market analysis released today projects the global extruded snacks market to surge from an estimated USD 89.9 billion in 2025 to USD 170.3 billion by 2035, demonstrating a robust Compound Annual Growth Rate (CAGR) of 6.6%. The market is set to deliver an impressive absolute dollar opportunity of USD 80.4 billion over the forecast period, driven by a global consumer shift towards convenient, shelf-stable, and healthier snack options. The
Global Banana Flakes Market Soars to USD 876.1 million by 2035, Driven by Health & Clean-Label Trends
Global Banana Flakes Market Soars to USD 876.1 million by 2035, Driven by Health …
A new market analysis reveals the global banana flakes market is set to expand significantly, projecting a robust Compound Annual Growth Rate (CAGR) of 4.6% from 2025 to 2035. The market, valued at USD 559.6 million in 2025, is forecast to reach USD 876.1 million by 2035, fueled by a rising consumer preference for natural, gluten-free, and plant-based ingredients in daily food choices. This press release offers a detailed look into
Confectionery Fillings Market Sweetens Global Outlook, Projected to Reach USD 2.2 Billion by 2035
Confectionery Fillings Market Sweetens Global Outlook, Projected to Reach USD 2. …
The global confectionery fillings market is poised for significant growth, with a new market analysis revealing a robust expansion fueled by a surge in consumer demand for innovative flavors and indulgent textures. According to the analysis, the market is estimated at USD 1381.2 million in 2025 and is projected to reach USD 2207.4 million by 2035, exhibiting a healthy compound annual growth rate (CAGR) of 4.8% during the forecast period. The
Water Softener Market to Skyrocket to USD 8.7 Billion by 2035, Driven by Smart Technology and Hard Water Crisis
Water Softener Market to Skyrocket to USD 8.7 Billion by 2035, Driven by Smart T …
A new market analysis reveals the global water softener market is poised for significant expansion, with a forecasted value of USD 8.7 billion by 2035. The report, covering the period from 2025 to 2035, projects a robust Compound Annual Growth Rate (CAGR) of 8.3%, up from an estimated USD 3.9 billion valuation in 2025. This surge is fueled by a combination of factors, including increasing consumer awareness of hard water's

All 5 Releases


More Releases for Primary

Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031. Primary Biliary Cholangitis (PBC), formerly known as
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk